Tuesday, 24 April 2012

Pp-Cap


Generic Name: propoxyphene (Oral route)

proe-POX-i-feen

Oral route(Capsule)

Do not prescribe propoxyphene for patients who are suicidal or addiction-prone. Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs, and patients who use alcohol in excess. Patients should not exceed the recommended dose and alcohol intake should be limited. Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths .


Oral route(Tablet)

Do not prescribe propoxyphene for patients who are suicidal or addiction-prone. Prescribe propoxyphene with caution for patients taking tranquilizers or antidepressant drugs, and patients who use alcohol in excess. Patients should not exceed the recommended dose and alcohol intake should be limited. Propoxyphene products in excessive doses, either alone or in combination with other CNS depressants, including alcohol, are a major cause of drug-related deaths .



Commonly used brand name(s)

In the U.S.


  • Darvon

  • Darvon-N

  • Pp-Cap

Available Dosage Forms:


  • Capsule

  • Tablet

  • Suspension

Therapeutic Class: Analgesic


Chemical Class: Opioid


Uses For Pp-Cap


Propoxyphene is used to relieve mild to moderate pain. It belongs to the group of medicines called narcotic analgesics (pain medicines). It acts on the central nervous system (CNS) to relieve pain.


When propoxyphene is used for a long time, it may become habit-forming, causing mental or physical dependence. However, people who have continuing pain should not let the fear of dependence keep them from using narcotics to relieve their pain. Mental dependence (addiction) is not likely to occur when narcotics are used for this purpose. Physical dependence may lead to withdrawal side effects if treatment is stopped suddenly. However, severe withdrawal side effects can usually be prevented by gradually reducing the dose over a period of time before treatment is stopped completely.


Products containing propoxyphene were withdrawn from the U.S. market starting November 19, 2010.


This medicine was available only with your doctor's prescription.


Before Using Pp-Cap


In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:


Allergies


Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.


Pediatric


Appropriate studies have not been performed on the relationship of age to the effects of propoxyphene in the pediatric population. Safety and efficacy have not been established.


Geriatric


Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of propoxyphene in the elderly. However, elderly patients are more likely to have age-related liver, kidney, or heart problems which may require caution and an adjustment in the dose for patients receiving propoxyphene.


Breast Feeding


Studies in women suggest that this medication poses minimal risk to the infant when used during breastfeeding.


Interactions with Medicines


Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.


  • Naltrexone

  • Rasagiline

  • Selegiline

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Adinazolam

  • Alfentanil

  • Alprazolam

  • Amobarbital

  • Anileridine

  • Aprobarbital

  • Bromazepam

  • Brotizolam

  • Buprenorphine

  • Butabarbital

  • Butalbital

  • Butorphanol

  • Carbamazepine

  • Carisoprodol

  • Chloral Hydrate

  • Chlordiazepoxide

  • Chlorzoxazone

  • Clobazam

  • Clonazepam

  • Clorazepate

  • Codeine

  • Dantrolene

  • Dezocine

  • Diazepam

  • Estazolam

  • Ethchlorvynol

  • Fentanyl

  • Flunitrazepam

  • Flurazepam

  • Fospropofol

  • Halazepam

  • Hydrocodone

  • Hydromorphone

  • Ketazolam

  • Levorphanol

  • Lorazepam

  • Lormetazepam

  • Medazepam

  • Meperidine

  • Mephenesin

  • Mephobarbital

  • Meprobamate

  • Metaxalone

  • Methocarbamol

  • Methohexital

  • Midazolam

  • Morphine

  • Morphine Sulfate Liposome

  • Nalbuphine

  • Nitrazepam

  • Nordazepam

  • Opium

  • Oxazepam

  • Oxycodone

  • Oxymorphone

  • Pentazocine

  • Pentobarbital

  • Phenobarbital

  • Prazepam

  • Propoxyphene

  • Quazepam

  • Remifentanil

  • Secobarbital

  • Sodium Oxybate

  • Sufentanil

  • Tapentadol

  • Temazepam

  • Thiopental

  • Triazolam

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.


  • Doxepin

  • Metoprolol

  • Propranolol

  • Warfarin

Interactions with Food/Tobacco/Alcohol


Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.


Other Medical Problems


The presence of other medical problems may affect the use of this medicine. Make sure you tell your doctor if you have any other medical problems, especially:


  • Alcohol abuse, history of or

  • Breathing problems (e.g., chronic obstructive pulmonary disease [COPD], cor pulmonale, hypoxia) or

  • Drug dependence, especially narcotic abuse or dependence, or history of—Use with caution. May increase risk for more serious side effects.

  • Brain tumor or

  • Head injuries or

  • Increased pressure in the head—Some of the side effects of propoxyphene can cause serious problems in people who have these medical problems.

  • Breathing problems (e.g., asthma, hypercapnia), severe or

  • Emotional problems or

  • Paralytic ileus (intestinal blockage) or

  • Respiratory depression (hypoventilation or slow breathing) or

  • Suicidal ideation (thoughts of hurting or killing oneself), or history of—Should not be used in patients with these conditions.

  • Hypotension (low blood pressure) or

  • Pancreatitis (inflammation of the pancreas)—Use with caution. May make these conditions worse.

  • Kidney disease or

  • Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body.

Proper Use of propoxyphene

This section provides information on the proper use of a number of products that contain propoxyphene. It may not be specific to Pp-Cap. Please read with care.


Take this medicine only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. This is especially important for elderly patients, who may be more sensitive to the effects of pain medicines. If too much of this medicine is taken for a long time, it may become habit-forming (causing mental or physical dependence).


This medicine should come with a Medication Guide. Read and follow these instructions carefully. Ask your doctor if you have any questions.


Dosing


The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.


The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.


  • For oral dosage forms (capsules or tablets):
    • For mild to moderate pain:
      • Adults—One capsule or tablet every 4 hours as needed. However, the dose is usually not more than 6 capsules or tablets per day.

      • Children—Use and dose must be determined by your doctor.



Missed Dose


If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.


Storage


Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.


Keep out of the reach of children.


Do not keep outdated medicine or medicine no longer needed.


Ask your healthcare professional how you should dispose of any medicine you do not use.


Throw any unused medicine by mixing it with used coffee grounds or kitty litter and place it in a sealable bag, empty can, or container.


Precautions While Using Pp-Cap


It is very important that your doctor check your progress while you are taking this medicine. This will allow your doctor to see if the medicine is working properly and to decide if you should continue to take it.


Talk to your doctor first before you stop taking this medicine and changing to another pain medicine.


This medicine can cause changes in heart rhythms, such as conditions called PR, QRS, and QT prolongation. It may change the way your heart beats and cause fainting, dizziness, lightheadedness, or serious side effects in some patients. Contact your doctor right away if you have any symptoms of heart rhythm problems, such as fast, pounding, or irregular heartbeats.


This medicine will add to the effects of alcohol and other CNS depressants (medicines that can make you drowsy or less alert). Some examples of CNS depressants are antihistamines or medicine for allergies or colds; sedatives, tranquilizers, or sleeping medicine; other prescription pain medicine or narcotics; medicine for seizures or barbiturates; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the other medicines listed above while you are using this medicine.


This medicine may be habit-forming. If you feel that the medicine is not working as well, do not use more than your prescribed dose.


Dizziness, lightheadedness, or fainting may occur when you get up suddenly from a lying or sitting position. Getting up slowly may help lessen this problem. Also, lying down for a while may relieve dizziness or lightheadedness.


This medicine may make you dizzy, drowsy, or lightheaded. Make sure you know how you react to this medicine before you drive, use machines, or do anything else that could be dangerous if you are dizzy or not alert.


Using narcotics for a long time can cause severe constipation. To prevent this, your doctor may direct you to take laxatives, drink a lot of fluids, or increase the amount of fiber in your diet. Be sure to follow the directions carefully, because continuing constipation can lead to more serious problems.


Do not change your dose or suddenly stop using this medicine without first checking with your doctor. Your doctor may want you to gradually reduce the amount you are using before stopping it completely. This may help prevent worsening of your condition and reduce the possibility of withdrawal symptoms, such as abdominal or stomach cramps, anxiety, fever, nausea, runny nose, sweating, tremors, or trouble with sleeping.


Using this medicine while you are pregnant may cause neonatal withdrawal syndrome in your newborn babies. Tell your doctor right away if your child has the following symptoms: abnormal sleep pattern, diarrhea, high-pitched cry, irritability, shakiness or tremor, weight loss, vomiting, or failure to gain weight.


Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.


Pp-Cap Side Effects


Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.


Check with your doctor immediately if any of the following side effects occur:


Rare
  • Abdominal or stomach pain

  • chills

  • clay-colored stools

  • dark urine

  • dizziness

  • fever

  • headache

  • itching

  • loss of appetite

  • nausea

  • rash

  • unpleasant breath odor

  • unusual tiredness or weakness

  • vomiting of blood

  • yellow eyes or skin

Incidence not known
  • Bloating

  • bloody or black, tarry stools

  • bloody or cloudy urine

  • change in consciousness

  • chest pain or discomfort

  • confusion

  • constipation

  • darkened urine

  • decreased urine output

  • difficult or troubled breathing

  • dilated neck veins

  • drowsiness

  • extreme fatigue

  • fainting

  • fast, slow, pounding, or irregular heartbeat or pulse

  • fever with or without chills

  • hives

  • hoarseness

  • indigestion

  • irregular, fast or slow, or shallow breathing

  • irritation

  • itching

  • joint pain, stiffness, or swelling

  • light-colored stools

  • loss of consciousness

  • muscle tremors

  • no blood pressure or pulse

  • no breathing

  • pain or discomfort in the arms, jaw, back, or neck

  • pains in the stomach, side, or abdomen, possibly radiating to the back

  • pale or blue lips, fingernails, or skin

  • rapid, deep breathing

  • redness of the skin

  • restlessness

  • right upper abdominal or stomach pain and fullness

  • severe stomach pain

  • shakiness and unsteady walk

  • shortness of breath

  • stomach cramps

  • stopping of the heart

  • sudden decrease in the amount of urine

  • swelling of the eyelids, face, fingers, lips, hands, lower legs, or feet

  • thoughts of suicide

  • tightness in the chest

  • troubled breathing or swallowing

  • unconsciousness

  • unsteadiness, trembling, or other problems with muscle control or coordination

  • vomiting of blood or material that looks like coffee grounds

  • weight gain

  • wheezing

Get emergency help immediately if any of the following symptoms of overdose occur:


Symptoms of overdose
  • Bluish color of the fingernails, lips, skin, palms, or nail beds

  • convulsion

  • coughing that sometimes produces a pink frothy sputum

  • decreased awareness or responsiveness

  • difficult, fast, or noisy breathing, sometimes with wheezing

  • dilated pupils

  • muscle tremors

  • pale skin

  • pounding or rapid pulse

  • rapid, deep breathing

  • severe sleepiness

  • sleepiness or unusual drowsiness

  • slow to respond

  • slurred speech

  • weight loss

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:


More common
  • Relaxed and calm

Incidence not known
  • Abnormal behavior

  • blurred or loss of vision

  • diarrhea

  • disturbed color perception

  • double vision

  • false or unusual sense of well-being

  • halos around lights

  • mental depression or anxiety

  • muscular pain, tenderness, wasting, or weakness

  • night blindness

  • nightmares or unusually vivid dreams

  • overbright appearance of lights

  • seeing, hearing, or feeling things that are not there

  • swelling of the eye

  • tunnel vision

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.


Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Pp-Cap side effects (in more detail)



The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.


The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.


More Pp-Cap resources


  • Pp-Cap Side Effects (in more detail)
  • Pp-Cap Use in Pregnancy & Breastfeeding
  • Pp-Cap Drug Interactions
  • Pp-Cap Support Group
  • 0 Reviews for Pp-Cap - Add your own review/rating


  • Propoxyphene Professional Patient Advice (Wolters Kluwer)

  • Darvon Prescribing Information (FDA)

  • Darvon Concise Consumer Information (Cerner Multum)

  • Darvon MedFacts Consumer Leaflet (Wolters Kluwer)

  • Darvon-N Prescribing Information (FDA)

  • Propoxyphene Hydrochloride Monograph (AHFS DI)



Compare Pp-Cap with other medications


  • Pain

Saturday, 21 April 2012

Arsenic Poisoning, Mild Medications


There are currently no drugs listed for "Arsenic Poisoning, Mild". See Arsenic Poisoning.





Drug List:

Timolide


Generic Name: Hydrochlorothiazide/Timolol (hye-droe-klor-oh-THYE-a-zide/TIM-oh-lole)
Brand Name: Timolide

Do not suddenly stop taking Timolide. Sharp chest pain, irregular heartbeat, and sometimes heart attack may occur if you suddenly stop Timolide. The risk may be greater if you have certain types of heart disease. Your doctor should slowly lower your dose over several weeks if you need to stop taking it. This should be done even if you only take Timolide for high blood pressure. Heart disease is common and you may not know you have it. Limit physical activity while you are lowering your dose. If new or worsened chest pain or other heart problems occur, contact your doctor right away. You may need to start taking Timolide again.





Timolide is used for:

Treating high blood pressure.


Timolide is a beta-blocker and diuretic combination. It works by decreasing the force and slowing down the heartbeat, helping the heart beat more regularly and reducing the amount of work the heart has to do. It also increases the elimination of excessive fluid, which helps to decrease blood pressure.


Do NOT use Timolide if:


  • you are allergic to any ingredient in Timolide or to sulfonamide medicines (eg, sulfamethoxazole, probenecid, glyburide)

  • you have uncontrolled heart failure, heart block, heart shock, a very slow heart rate, or low blood pressure

  • you are unable to urinate or have a history of asthma or severe chronic obstructive pulmonary disease (COPD)

  • you are taking other beta-blockers (eg, propranolol), dofetilide, or mibefradil

Contact your doctor or health care provider right away if any of these apply to you.



Before using Timolide:


Some medical conditions may interact with Timolide. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of bronchitis, lung disease (eg, COPD), diabetes, gout, an overactive thyroid, heart problems (eg, congestive heart failure), blood vessel problems, pheochromocytoma, lupus, liver disease, kidney problems, or abnormal blood electrolyte (eg, potassium sodium) levels

  • if you are having surgery, receiving anesthesia, or you are dehydrated

Some MEDICINES MAY INTERACT with Timolide. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Barbiturates (eg, phenobarbital), cimetidine, clonidine, corticosteroids (eg, prednisone), guanethidine, other beta-blockers (eg, propranolol), or reserpine because they may increase the risk of Timolide's side effects

  • Nonsteroidal anti-inflammatory drugs (NSAIDs) (eg, ibuprofen), phenytoin, or rifampin because they may decrease Timolide's effectiveness

  • Antiarrhythmics (eg, disopyramide), calcium channel blockers (eg, verapamil, diltiazem), or cimetidine because side effects, such as slow or irregular heart beat or low blood pressure, may occur

  • Angiotensin-converting enzyme (ACE) inhibitors (eg, enalapril), barbiturates (eg, phenobarbital), chlorpromazine, clonidine, diazoxide, flecainide, mefloquine, mibefradil, narcotics (eg, codeine), or nifedipine because the risk of side effects of both medicines may be increased

  • Allopurinol, amantadine, digitalis (eg, digoxin), dofetilide, insulin or other medicines for diabetes (eg, glyburide), ketanserin, lithium, theophylline, or thyroxine because the risk of their side effects may be increased by Timolide

This may not be a complete list of all interactions that may occur. Ask your health care provider if Timolide may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Timolide:


Use Timolide as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Timolide by mouth with or without food.

  • If you also take cholestyramine or colestipol, do not take them within 1 before or 2 hours after taking Timolide. Check with your doctor if you have questions.

  • Timolide may increase the amount of urine or cause you to urinate more often when you first start taking it. To keep this from disturbing your sleep, try to take your dose before 6 pm.

  • If you miss a dose of Timolide, take the missed dose if you remember the same day. Skip the missed dose if you do not remember the same day. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Timolide.



Important safety information:


  • Timolide may cause drowsiness, dizziness, or lightheadedness. These effects may be worse if you take it with alcohol or certain medicines. Use Timolide with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Timolide may cause dizziness, lightheadedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Patients who take medicine for high blood pressure often feel tired or run down for a few weeks after starting treatment. Be sure to take your medicine even if you may not feel "normal." Tell your doctor if you develop any new symptoms.

  • Timolide may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Timolide. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Tell your doctor or dentist that you take Timolide before you receive any medical or dental care, emergency care, or surgery.

  • If you have high blood pressure, do not use nonprescription products that contain stimulants. These products may include diet pills or cold medicines. Contact your doctor if you have any questions or concerns.

  • Diabetes patients - Timolide may hide signs of low blood sugar, such as a rapid heartbeat. Be sure to watch for other signs of low blood sugar. Low blood sugar may make you anxious, sweaty, weak, dizzy, drowsy, or faint. It may also make your vision change; give you a headache, chills, or tremors; or make you more hungry. Check blood sugar levels closely. Ask your doctor before you change the dose of your diabetes medicine.

  • Timolide may interfere with certain lab tests, including parathyroid function tests. Be sure your doctor and lab personnel know you are taking Timolide.

  • Lab tests, including blood pressure, blood electrolyte levels, and heart rate, may be performed while you use Timolide. These tests may be used to monitor your condition or check for side effects. Be sure to keep all doctor and lab appointments.

  • Use Timolide with caution in the ELDERLY; they may be more sensitive to its effects.

  • Timolide should be used with extreme caution in CHILDREN; safety and effectiveness in children have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Timolide while you are pregnant. Timolide is found in breast milk. Do not breast-feed while taking Timolide.


Possible side effects of Timolide:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Cough; dizziness; drowsiness; lightheadedness; tiredness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); chest pain; confusion; decreased urination; dry mouth; loss of consciousness; muscle pain or weakness; nausea; slow or irregular heartbeat; swelling of ankles or feet; tremors; unusual thirst or fatigue; vomiting.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Timolide side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include coughing; dizziness; drowsiness; fainting; loss of consciousness; muscular weakness; nausea; seizures; slow heartbeat; trouble breathing; upset stomach; vomiting; weakness.


Proper storage of Timolide:

Store Timolide at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Timolide out of the reach of children and away from pets.


General information:


  • If you have any questions about Timolide, please talk with your doctor, pharmacist, or other health care provider.

  • Timolide is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

This information is a summary only. It does not contain all information about Timolide. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Timolide resources


  • Timolide Side Effects (in more detail)
  • Timolide Use in Pregnancy & Breastfeeding
  • Timolide Drug Interactions
  • Timolide Support Group
  • 0 Reviews for Timolide - Add your own review/rating


Compare Timolide with other medications


  • High Blood Pressure

Friday, 20 April 2012

Tarivid IV Infusion Solution





Tarivid 2mg/ml Solution for Infusion



ofloxacin







Is this leaflet hard to see or read?



Phone 01483 505515 for help




Read all of this leaflet carefully before you start taking this medicine



  • Keep this leaflet. You may need to read it again

  • If you have any further questions, ask your doctor or pharmacist

  • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours

  • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.




In this leaflet:



  • 1. What Tarivid is and what it is used for

  • 2. Before you have Tarivid

  • 3. How Tarivid is given

  • 4. Possible side effects

  • 5. How to store Tarivid

  • 6. Further information





What Tarivid is and what it is used for





The name of your medicine is Tarivid 2mg/ml Solution for Infusion (called Tarivid throughout this leaflet). Tarivid infusion contains a medicine called ofloxacin. This belongs to a group of medicines called antibiotics. It works by killing bacteria that cause infections.




Tarivid is used for infections of the:



  • Kidneys or bladder (urinary tract)

  • Chest or lungs

  • Blood

  • Skin and soft tissue. Soft tissue is underneath the skin and includes muscle





Before you have Tarivid






Do not take this medicine and tell your doctor if:



  • You are allergic (hypersensitive) to ofloxacin or any of the other ingredients of Tarivid
    (listed in Section 6 below)
    Signs of an allergic reaction include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue

  • You have ever had swelling of the tendons (called tendinitis) which can affect areas such as the wrist or the achilles tendon

  • You have epilepsy or are at risk of fits

  • You have a problem with your red blood cells known as ‘glucose-6-dehydrogenase deficiency’

  • You are pregnant or breast-feeding (see ‘Pregnancy and breast-feeding’ section below)

  • You are under 18 years of age or are still growing

Do not have this medicine if any of the above apply to you. If you are not sure, talk to your nurse, doctor or pharmacist before having Tarivid.








Take special care with Tarivid



Check with your doctor, pharmacist or nurse before having your medicine if:



  • You have liver or kidney problems

  • You are elderly

  • You have heart disease or problems with your heartbeat

  • You are taking medicines that can affect your heart or lower your blood pressure (see section below on ‘Taking other medicines’)

  • You have low levels of potassium or magnesium in your blood

  • You have or have ever had any mental health problems

  • You have porphyria (a rare illness which affects the metabolism)

  • You are going to have an operation under general anaesthetic whilst being treated with Tarivid

If you are not sure if any of the above apply to you, talk to your doctor, pharmacist or nurse before having Tarivid.







Taking other medicines



Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines. This includes medicines you buy without a prescription, including herbal medicines. This is because Tarivid and some other medicines can affect the way each other work.



In particular, tell your doctor if you are taking the following medicine:



  • Methotrexate used for rheumatism or cancer




The following medicines can change the way Tarivid works or Tarivid may change the way some of these medicines work:



  • Medicines used to stop your blood from clotting

  • Medicines used for high blood pressure or medicines that lower blood pressure

  • Medicines that help put you to sleep (anaesthetics)

  • Water tablets (diuretics) such as furosemide

  • Glibenclamide – used for diabetes

  • Probenecid – used for gout

  • Cimetidine – used for stomach ulcers or indigestion




The following medicines, when taken with Tarivid, can increase the chance of you getting side effects



  • Other antibiotics (such as erythromycin, azithromycin or clarithromycin)

  • Medicines for depression (such as amitriptyline, clomipramine or imipramine)

  • Theophylline – used for breathing problems

  • Medicines used to control your heartbeat (such as amiodarone, quinidine, procainamide, or disopyramide)

  • Non steroidal anti-inflammatory drugs (NSAIDs) – used for pain relief and inflammation (such as ibuprofen, diclofenac or indometacin)

  • Corticosteroids – used for inflammation




Having Tarivid with food and drink



Do not drink alcohol while having Tarivid. This is because it may make you feel dizzy or sleepy.





Pregnancy and breast-feeding



Do not have this medicine if:



  • You are pregnant, might become pregnant or think you may be pregnant


  • You are breast-feeding or planning to breast-feed

Ask your doctor or pharmacist for advice before taking any medicine if you are pregnant or breast-feeding.







Driving and using machines



You may feel sleepy or dizzy or have problems with your eyesight while having this medicine. If this happens, do not drive or use any tools or machines.





Important information about some of the ingredients of Tarivid



Tarivid infusion contains sodium. There is 354mg of sodium per 2mg of infusion. This may be harmful to people on a low sodium or low salt diet.






How Tarivid is given




Having this medicine



  • Your doctor or nurse will normally give you Tarivid. This is because it needs to be given as a slow infusion (drip) into a vein

  • When having Tarivid, avoid strong sunlight and do not use sun lamps or solaria

If you are not sure why you are receiving Tarivid or have any questions about how much Tarivid is being given to you, speak to your doctor, pharmacist or nurse.





How long you will have Tarivid



  • The length of your treatment will depend on how serious your infection is

  • The medicine is usually given for 5 to 10 days and treatment should not be longer than 2 months

  • Once your illness has improved your doctor may change your medicine to Tarivid tablets




How much will be given to you



  • Your doctor will decide on how much Tarivid you should have

  • The dose will depend on the type of infection you have

The usual dose for adults, including the elderly, is between 200 mg and 800 mg each day. The dose depends on the location and type of infection:



  • Kidney or bladder infections (urinary tract):
    200 mg each day

  • Chest or lung infections:
    200 mg twice a day

  • Blood infections:
    200 mg twice a day


  • Skin and soft tissue infections:
    400 mg twice a day



Kidney or liver problems




If you have any kidney or liver problems you may be given a lower dose.



Children and Adolescents:

This medicine should not be given to children or adolescents.





If you have more Tarivid than you should



Your doctor will carefully calculate how much Tarivid you should get. Therefore it is unlikely your doctor, nurse or pharmacist will give you too much of this medicine. But, if you think that you have been given too much or too little Tarivid, tell your doctor, nurse or pharmacist. The following effects may happen: confusion, feeling dizzy, loss of consciousness, convulsion, seizures (fits), nausea or bleeding in stools.





If you forget to have Tarivid



Your doctor or nurse will have instructions about when to give you your medicine. It is unlikely that you will not be given the medicine as it has been prescribed. If you think that you may have missed a dose, then talk to your doctor or nurse.





If you stop having Tarivid



Keep having Tarivid until your doctor tells you to stop. Do not stop having Tarivid just because you feel better. It is important for you to keep having Tarivid injections until your doctor decides to stop them. If you stop, your infection may get worse again.





Urine Tests



Having Tarivid may affect the results of some urine tests. If you are going to have a urine test, it is important to tell your doctor you are having Tarivid.






If you have any further questions on the use of this product, ask your doctor, pharmacist or nurse.





Possible side effects





Like all medicines, Tarivid can cause side effects, although not everybody gets them.




Tell a nurse or doctor straight away if you have any of the following serious side effects:



  • You have an allergic reaction. The signs may include: a rash, swallowing or breathing problems, swelling of your lips, face, throat or tongue

Very Rare (affects less than 1 in 10,000 people)



  • An uneven or fast heartbeat, you may also feel faint

  • Watery diarrhoea, which may have blood in it, possibly with stomach cramps and a high temperature

  • Fits

  • Hearing problems or hearing loss

  • Liver problems that may cause your eyes or skin to go yellow (jaundice)

  • Severe skin rashes which may include blistering or peeling of the skin around the lips, eyes, mouth, nose and genitals

  • Skin rashes caused by strong sunlight

  • Feeling faint, light-headed or dizzy, due to low blood pressure

  • Muscle weakness, joint and muscle pains

  • Feeling weak or irritable, sweating and/or trembling. This could be due to lowering of blood sugar levels

  • Feeling thirsty and passing water more often than usual. This could be due to a rise in blood sugar levels

  • Swelling or discomfort in your tendons, such as in the achilles tendon

  • Severe inflammation of the kidneys, which may result in your kidneys stopping working. Signs may include a rash, high temperature and general aches and pains

  • Severe depression or mental illness. Some people who are depressed think of harming or killing themselves

Rare (affects less than 1 in 1000 people)



  • Numbness or tingling in the hands and feet or being very sensitive to touch




Tell your doctor if any of the following side effects gets serious or lasts longer than a few days:



Uncommon (affects less than 1 in 100 people)



  • Feeling or being sick, diarrhoea or stomach pains

  • Headaches, sleeping problems, feeling dizzy or restless

  • Skin rash or itching

Rare (affects less than 1 in 1000 people)



  • Loss of appetite

  • Feeling confused or anxious, nightmares, seeing things that are not there, depression and mental illness, feeling
    drowsy, trembling, problems walking due to poor muscle control

  • Changes in eyesight

  • Changes in or loss of your sense of taste or smell

  • Changes in levels of liver enzymes shown in blood tests

  • A general feeling of being unwell

  • Pain, redness or swelling on the vein or area you have been injected with Tarivid

Very Rare (affects less than 1 in 10,000 people)



  • Feeling tired, faint, dizzy and having pale skin. These could be signs of anaemia

  • You may bruise more easily than usual. This could be because of a blood problem called ‘thrombocytopenia’

  • You may feel weak, bruise more easily and get more infections than usual. This could be because of a blood problem called ‘pancytopenia’

  • Cough or shortness of breath, caused by lung inflammation

It is possible that Tarivid may trigger an attack of porphyria (a rare illness which affects the metabolism) in some patients.




Talk to your doctor or pharmacist if any of the side effects gets serious or lasts longer than a few days, or if you notice any side effects not listed in this leaflet.





How to store Tarivid



This medicine will be kept by your doctor or pharmacist in a safe place where children cannot see or reach it.



Store in the original packaging to protect from light.



Do not use Tarivid after the expiry date, which is stated on the label. The expiry refers to the last day of that month.



Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.





Further Information




What Tarivid contains



  • Each 1ml contains 2mg of the active substance, ofloxacin

  • The other ingredients are sodium chloride, hydrochloric acid and water for injections




What Tarivid looks like and contents of the pack



Tarivid is a clear greenish-yellow solution in 100ml glass bottles with grey chlorobutyl rubber closures and aluminium caps.





Marketing Authorisation Holder and Manufacturer



Marketing Authorisation Holder




Sanofi-aventis

One Onslow Street

Guildford

Surrey

GU1 4YS

UK

Tel:01483 505515

Fax:01483 535432

email:uk-medicalinformation@sanofi-aventis.com



Manufacturer




Sanofi-Aventis Deutschland GmbH

Bruningstrasse 50

D-65926 Frankfurt am Main

Germany




This leaflet does not contain all the information about your medicine. If you have any questions or are not sure about anything, ask your doctor or pharmacist.



This leaflet was last revised in May 2008



© Sanofi-aventis, 2002 – 2008




180972





Thursday, 19 April 2012

Helium




Helium, COMPRESSED

       



Helium, COMPRESSED


UN1046


USP


NON-FLAMMABLE GAS 2


MEDICAL GAS


Rx only


Linde


WARNING: Administration of Helium may be hazardous or contraindicated. For use only by or under the supervision of a licensed practitioner who is experienced in the use and administration of Helium and is familiar with the indications, effect, dosages, methods and frequency and duration of administration, and the hazards, methods and frequency and duration of administration, and the hazards, contraindication and side effects and the precautions to be taken. When used as a diluent for oxygen to produce respirable mixtures, user must assure sufficient oxygen concentration to sustain life.


CAUTION: HIGH PRESSURE GAS CAN CAUSE RAPID SUFFOCATION. Open valve slowly and close after each use. Keep away from heat, flame or sparks. Do not strike arc or laser beam on cylinder. Transport, store, and use with adequate ventilation. Use equipment rated for cylinder pressure. Use a back flow preventive device in the piping. Cylinder temperature should not exceed 52°C (125°F). Always secure cylinder in upright position. Return cylinder with 25 psig pressure. Return cylinder with cylinder cap secured, if applicable. Use this product in accordance with it's specific Material Safety Data Sheet, available at Web Site: www.lindeus.com. FIRST AID: IF INHALED, remove to fresh air. If not breathing, give artificial respiration. If breathing is is difficult, give oxygen. Call a physician.


DO NOT REMOVE THIS PRODUCT LABEL.















CONTENTS:
Cylinder

Type
Liters  
K5688[_]
M2830[_]
_____________________

Distributed by:

Linde Gas North America LLC

Linde

575 Mountain Ave.

Murray Hill, NJ 07974


CAS 7440-59-7


L&SP 4014 MG006D









Helium  
Helium  gas










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)25373-010
Route of AdministrationRESPIRATORY (INHALATION)DEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Helium (Helium)Helium99 L  in 100 L





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
125373-010-045688 L In 1 CYLINDERNone
225373-010-052830 L In 1 CYLINDERNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved medical gas11/27/1990


Labeler - Linde Gas North America LLC (805568339)









Establishment
NameAddressID/FEIOperations
Linde Gas North America LLC010263301MANUFACTURE
Revised: 12/2011Linde Gas North America LLC



Tuesday, 17 April 2012

Sitrex


Generic Name: guaifenesin and phenylephrine (gwye FEN e sin and FEN il EFF rin)

Brand Names: Aldex G, Aquatab D, Crantex, D-Phen 1000, D-Tab, Deconex, Deconsal II, Deconsal Pediatric, Despec, Donatussin Drops, Duomax, Duraphen 1000, Duraphen II, Duratuss, Dynex LA, ExeTuss, Extendryl G, Fenesin PE IR, Genexa LA, Gentex LA, Gilphex TR, Guaiphen-D 1200, Guaiphen-D 600, Guaiphen-PD, Guiadex PD, Guiatex PE, J-Max, Liquibid D-R, Liquibid-D, Liquibid-PD, Lusonex, Maxiphen, Medent-PE, MontePhen, Mucinex Children's Cold, Mucus Relief Sinus, Mydex, Nariz, Nasex, Nescon-PD, Nexphen PD, Norel EX, PE-Guai, Pendex, Prolex D, Refenesen PE, Reluri, Rescon-GG, Respa-PE, Robitussin Head & Chest Congestion, Simuc, Simuc-GP, Sina-12X, Sinupan, SINUvent PE, Sitrex PD, Sudafed PE Non-Drying Sinus, Sudex, Triaminic Chest & Nasal Congestion, Visonex, Wellbid-D, Xedec, Xedec II, Xpect-PE, Zotex GPX


What is Sitrex (guaifenesin and phenylephrine)?

There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Guaifenesin is an expectorant. It helps loosen congestion in your chest and throat, making it easier to cough out through your mouth.


Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).


The combination of guaifenesin and phenylephrine is used to treat stuffy nose and sinus congestion, and to reduce chest congestion caused by the common cold or flu.


Guaifenesin and phenylephrine may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Sitrex (guaifenesin and phenylephrine)?


There are many brands and forms of guaifenesin and phenylephrine available and not all brands are listed on this leaflet.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

What should I discuss with my healthcare provider before taking Sitrex (guaifenesin and phenylephrine)?


You should not use this medication if you are allergic to guaifenesin or phenylephrine, or to other decongestants, diet pills, stimulants, or ADHD medications. Do not use guaifenesin and phenylephrine if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. Serious, life threatening side effects can occur if you use guaifenesin and phenylephrine before the MAO inhibitor has cleared from your body.

Ask a doctor or pharmacist if it is safe for you to take this medication if you have:



  • heart disease or high blood pressure;




  • diabetes;




  • circulation problems;




  • glaucoma;




  • overactive thyroid; or




  • enlarged prostate or problems with urination.




It is not known if this medication may be harmful to an unborn baby. Do not use this medication without your doctor's advice if you are pregnant. This medication passes into breast milk and could harm a nursing baby. Do not use this medication without telling your doctor if you are breast-feeding a baby.

Artificially-sweetened liquid forms of cold medicine may contain phenylalanine. This would be important to know if you have phenylketonuria (PKU). Check the ingredients and warnings on the medication label if you are concerned about phenylalanine.


How should I take Sitrex (guaifenesin and phenylephrine)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended. Cold medicine is usually taken only for a short time until your symptoms clear up.


Do not give this medication to a child younger than 4 years old. Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children.

Measure the liquid form of this medicine with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one.


Do not crush, chew, break, or open an extended-release tablet or capsule. Swallow it whole. Breaking or opening the pill may cause too much of the drug to be released at one time. Take guaifenesin and phenylephrine with food if it upsets your stomach. Talk with your doctor if your symptoms do not improve after 7 days of treatment, or if you have a fever with a headache, cough, or skin rash. Drink extra fluids to help loosen the congestion and lubricate your throat while you are taking this medication. Store at room temperature away from moisture and heat.

What happens if I miss a dose?


Since cough or cold medicine is taken as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose symptoms may include nausea, vomiting, numbness or tingly feeling, dizziness, and feeling restless or nervous.


What should I avoid while taking Sitrex (guaifenesin and phenylephrine)?


This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Drinking alcohol can increase certain side effects of guaifenesin and phenylephrine. Ask a doctor or pharmacist before using any other cough, cold, or allergy medicine. Guaifenesin and phenylephrine are contained in many combination medicines. Taking certain products together can cause you to get too much of a certain drug. Check the label to see if a medicine contains guaifenesin or phenylephrine.

Avoid taking this medication with diet pills, caffeine pills, or other stimulants (such as ADHD medications) without your doctor's advice. Taking a stimulant together with a decongestant can increase your risk of unpleasant side effects.


Sitrex (guaifenesin and phenylephrine) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using this medication and call your doctor at once if you have any of these serious side effects:

  • fast, pounding, or uneven heartbeat;




  • severe dizziness, anxiety, restless feeling, or nervousness;




  • easy bruising or bleeding, unusual weakness, fever, chills, body aches, flu symptoms;




  • dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure); or




  • nausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).



Less serious side effects may include:



  • vomiting, upset stomach;




  • warmth, tingling, or redness under your skin;




  • feeling excited or restless (especially in children);




  • sleep problems (insomnia);




  • skin rash or itching;




  • headache; or




  • dizziness.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Sitrex (guaifenesin and phenylephrine)?


Ask a doctor or pharmacist if it is safe for you to take guaifenesin and phenylephrine if you are also using any of the following drugs:



  • medicines to treat high blood pressure;




  • a beta-blocker such as atenolol (Tenormin, Tenoretic), carvedilol (Coreg), labetalol (Normodyne, Trandate), metoprolol (Dutoprol, Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal, InnoPran), sotalol (Betapace), and others; or




  • an antidepressant such as amitriptyline (Elavil, Vanatrip, Limbitrol), doxepin (Sinequan, Silenor), desipramine (Norpramin), imipramine (Janimine, Tofranil), nortriptyline (Pamelor), and others.



This list is not complete and other drugs may interact with guaifenesin and phenylephrine. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Sitrex resources


  • Sitrex Side Effects (in more detail)
  • Sitrex Use in Pregnancy & Breastfeeding
  • Sitrex Drug Interactions
  • Sitrex Support Group
  • 0 Reviews for Sitrex - Add your own review/rating


  • Crantex Prescribing Information (FDA)

  • Despec Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Entex LA Sustained-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gentex LA Sustained-Release Tablets (12 Hour) MedFacts Consumer Leaflet (Wolters Kluwer)

  • Guiatex PE Prescribing Information (FDA)

  • Lusonex Controlled-Release Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Rescon-GG Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

  • Sina-12X Suspension MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Sitrex with other medications


  • Cough and Nasal Congestion
  • Sinus Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about guaifenesin and phenylephrine.

See also: Sitrex side effects (in more detail)


Myambutol


Generic Name: Ethambutol Hydrochloride
Class: Antituberculosis Agents
VA Class: AM500
CAS Number: 1070-11-7

Introduction

Antituberculosis agent.103 106 a


Uses for Myambutol


Tuberculosis


Treatment of active (clinical) tuberculosis (TB) in conjunction with other antituberculosis agents.103 c d e


First-line agent for treatment of pulmonary TB; used in the initial intensive treatment phase.106


First-line agent for management of drug-resistant pulmonary TB.106


For initial treatment of active TB caused by drug-susceptible M. tuberculosis, recommended multiple-drug regimens consist of an initial intensive phase (2 months) and a continuation phase (4 or 7 months).106 109 Although the usual duration of treatment for drug-susceptible pulmonary and extrapulmonary TB (except disseminated infections and TB meningitis) is 6–9 months,106 109 ATS, CDC, and IDSA state that completion of treatment is determined more accurately by the total number of doses and should not be based solely on the duration of therapy.106 A longer duration of treatment (e.g., 12–24 months) usually is necessary for infections caused by drug-resistant M. tuberculosis.106 109


Patients with treatment failure or drug-resistant M. tuberculosis, including multidrug-resistant (MDR) TB (resistant to both isoniazid and rifampin) or extensively drug-resistant (XDR) TB (resistant to both isoniazid and rifampin and also resistant to a fluoroquinolone and at least one parenteral second-line antimycobacterial such as capreomycin, kanamycin, or amikacin), should be referred to or managed in consultation with experts in the treatment of TB as identified by local or state health departments or CDC.106


Mycobacterium avium Complex (MAC) Infections


Treatment of M. avium complex (MAC) infections† in conjunction with other antimycobacterials, including infections in HIV-infected adults, adolescents, or children†.107 c d


For initial treatment of nodular/bronchiectatic pulmonary disease caused by macrolide-susceptible MAC, ATS and IDSA recommend a 3-times weekly regimen of clarithromycin (or azithromycin), ethambutol, and rifampin in most patients.107 For initial treatment of fibrocavitary or severe nodular/bronchiectatic pulmonary disease caused by macrolide-susceptible MAC, ATS and IDSA recommend a daily regimen of clarithromycin (or azithromycin), ethambutol, and rifampin (or rifabutin) and state that consideration can be given to adding amikacin or streptomycin during the first 2–3 months of treatment for extensive (especially fibrocavitary) disease or when previous therapy has failed.107 Although a 2-drug regimen of clarithromycin (or azithromycin) and ethambutol may be adequate for treatment of nodular/bronchiectatic MAC disease in some patients, such regimens should not be used for fibrocavitary disease because of the risk of emergence of macrolide resistance.107


For treatment of disseminated MAC disease, including in HIV-infected individuals, ATS, CDC, NIH, and IDSA recommend a regimen of clarithromycin (or azithromycin) and ethambutol with or without rifabutin.107 c d


Treatment of MAC infections is complicated and should be directed by clinicians familiar with mycobacterial diseases; consultation with a specialist is particularly important when the patient cannot tolerate first-line drugs or when the infection has not responded to prior therapy or is caused by macrolide-resistant MAC.107


Prevention of recurrence (secondary prophylaxis) of disseminated MAC infections† in HIV-infected adults, adolescents, and children†.108 c d USPHS/IDSA, CDC, NIH, IDSA, and others recommend clarithromycin (or azithromycin) given with ethambutol (with or without rifabutin) for secondary prophylaxis after the initial infection has been treated.108 c


Not used for primary prevention (primary prophylaxis) of disseminated MAC infection in HIV-infected individuals.108 Drug of choice for primary prophylaxis is azithromycin or clarithromycin;107 108 rifabutin (with or without azithromycin) is an alternative.107 108


Mycobacterium kansasii and Other Mycobacterial Infections


Treatment of M. kansasii† infections in conjunction with other antimycobacterials.107 g ATS and IDSA recommend a regimen of isoniazid, rifampin, and ethambutol for treatment of pulmonary or disseminated infections caused by rifampin-susceptible M. kansasii.107 If rifampin-resistant M. kansasii are involved, ATS and IDSA recommend a 3-drug regimen based on results of in vitro susceptibility, including clarithromycin (or azithromycin), moxifloxacin, ethambutol, sulfamethoxazole, or streptomycin.107


Treatment of M. marinum† infections in conjunction with other antimycobacterials (e.g., clarithromycin and/or rifampin).107 i j l Optimum regimens not identified.107 i j l Monotherapy (minocycline, clarithromycin, doxycycline, co-trimoxazole) may be effective for superficial cutaneous infections,j but a multiple-drug regimen usually used for severe cutaneous infections or infections in immunocompromised individuals.i j


Treatment of M. xenopi† infections in conjunction with other antimycobacterials.107 Optimum regimens not established; in vivo response may not correlate with in vitro susceptibility.107 ATS and IDSA state that a regimen of clarithromycin, rifampin, and ethambutol generally has been used, although rate of relapse is high.107 A regimen of isoniazid, rifampin (or rifabutin), ethambutol, and clarithromycin (with or without streptomycin during initial treatment) also has been suggested.107


Myambutol Dosage and Administration


Administration


Oral Administration


Administer orally without regard to meals.103 e


Dosage


Available as ethambutol hydrochloride; dosage expressed in terms of the salt.103 e


Must be used in conjunction with other antimycobacterial agents for treatment of active (clinical) TB,103 108 e treatment or prevention of MAC infections†,107 108 c or treatment of other mycobacterial infections†.107


Can be used in daily or intermittent (e.g., 2 or 3 times weekly) multiple-drug TB regimens.106 109 c d


Pediatric Patients


Tuberculosis

Treatment of Active (Clinical) Tuberculosis in Children†

Oral

Children <15 years of age or weighing ≤40 kg†: 15–25 mg/kg once daily recommended by ATS, CDC, IDSA, AAP, and others.106 109 d h If an intermittent regimen is used, 50 mg/kg twice weekly.106 109 d h ATS, CDC, and IDSA recommend that children receive a maximum of 1 g per dose;106 d AAP and others recommend a maximum of 2.5 g per dose.109 h


Treatment of Active (Clinical) Tuberculosis in Adolescents

Oral

Adolescents ≥15 years of age weighing 40–55 kg: 800 mg daily, 2 g twice weekly, or 1.2 g 3 times weekly recommended by ATS, CDC, and IDSA.106


Adolescents ≥15 years of age weighing 56–75 kg: 1.2 g daily, 2.8 g twice weekly, or 2 g 3 times weekly recommended by ATS, CDC, and IDSA.106


Adolescents ≥15 years of age weighing 76-90 kg: 1.6 g daily, 4 g twice weekly, or 2.4 g 3 times weekly recommended by ATS, CDC, and IDSA.106


Adolescents: AAP and others recommend 15–25 mg/kg (up to 2.5 g) once daily or 50 mg/kg twice weekly (up to 2.5 g per dose).109 h


Mycobacterium avium Complex (MAC) Infections†

Treatment of Disseminated MAC in HIV-infected Children†

Oral

15–25 mg/kg (up to 1 g) once daily.d h Used in conjunction with clarithromycin (7.5–15 mg/kg [up to 500 mg] twice daily) or azithromycin (10–12 mg/kg [up to 500 mg] once daily) with or without rifabutin (10–20 mg/kg [up to 300 mg] once daily).d


Treatment of Disseminated MAC in HIV-infected Adolescents†

Oral

15 mg/kg once daily in conjunction with either clarithromycin (500 mg twice daily) or azithromycin (500 mg once daily) with or without rifabutin (300 mg once daily).107 c


Prevention of MAC Recurrence (Secondary Prophylaxis) in HIV-infected Children†

Oral

15 mg/kg (up to 900 mg) once daily.108 h Used in conjunction with clarithromycin (7.5 mg/kg [up to 500 mg] twice daily) or azithromycin (5 mg/kg [up to 250 mg] once daily) with or without rifabutin (5 mg/kg [up to 300 mg] once daily).108


Secondary prophylaxis to prevent MAC recurrence in HIV-infected children usually continued for life.108 The safety of discontinuing secondary MAC prophylaxis in children whose CD4+ T-cell count increases in response to antiretroviral therapy has not been studied.108


Prevention of MAC Recurrence (Secondary Prophylaxis) in HIV-infected Adolescents†

Oral

15 mg/kg (up to 900 mg) once daily.108 c h Used in conjunction with either clarithromycin (500 mg twice daily) or azithromycin (500 mg once daily) with or without rifabutin (300 mg once daily).108 c


Secondary prophylaxis to prevent MAC recurrence usually continued for life in HIV-infected adolescents.108 c


Consideration can be given to discontinuing such prophylaxis after ≥12 months in those who remain asymptomatic with respect to MAC and have an increase in CD4+ T-cell count to >100/mm3 that has been sustained for ≥6 months.108 c Reinitiate prophylaxis if CD4+ T-cell count decreases to <100/mm3.108 c


Adults


Tuberculosis

Treatment of Active (Clinical) Tuberculosis

Oral

Manufacturers recommend 15 mg/kg once daily in previously untreated adults.103 e In previously treated adults, manufacturers recommend 25 mg/kg once daily for 60 days, followed by 15 mg/kg once daily.103 e


Adults weighing 40–55 kg: 800 mg once daily, 2 g twice weekly, or 1.2 g 3 times weekly recommended by ATS, CDC, and IDSA.106 c


Adults weighing 56–75 kg: 1.2 g once daily, 2.8 g twice weekly, or 2 g 3 times weekly recommended by ATS, CDC, and IDSA.106 c


Adults weighing 76-90 kg: 1.6 g once daily, 4 g twice weekly, or 2.4 g 3 times weekly recommended by ATS, CDC, and IDSA.106 c


Mycobacterium avium Complex (MAC) Infections†

Initial Treatment of Pulmonary MAC Infections (Nodular/bronchiectatic Disease) Caused by Macrolide-susceptible Strains†

Oral

25 mg/kg 3 times weekly in conjunction with rifampin (600 mg 3 times weekly) and either clarithromycin (1 g 3 times weekly) or azithromycin (500 mg 3 times weekly) recommended by ATS and IDSA.107 Continue until patient has been culture negative on treatment for 1 year.107


Intermittent (3-times weekly) regimen is not recommended for those with cavitary or moderate or severe disease or those who have been previously treated.107


Initial Treatment of Pulmonary MAC Infections (Fibrocavitary or Severe Nodular/bronchiectatic Disease) Caused by Macrolide-susceptible Strains†

Oral

15 mg/kg once daily in conjunction with either rifampin (10 mg/kg [up to 600 mg] once daily) or rifabutin (150–300 mg once daily) and either clarithromycin (0.5–1 g daily) or azithromycin (250 mg once daily) recommended by ATS and IDSA.107 Continue until patient has been culture negative on treatment for 1 year.107 Consideration can be given to including amikacin or streptomycin 3-times weekly during the first 2–3 months of treatment for extensive, especially fibrocavitary, disease or when previous therapy has failed.107


Treatment of Disseminated MAC in HIV-infected and Other Adults†

Oral

15 mg/kg once daily in conjunction with either clarithromycin (500 mg twice daily) or azithromycin (500 mg once daily) with or without rifabutin (300 mg once daily) recommended by ATS, CDC, and IDSA.107 c


Prevention of MAC Recurrence (Secondary Prophylaxis) in HIV-infected Adults†

Oral

15 mg/kg once daily.108 c Used in conjunction with either clarithromycin (500 mg twice daily) or azithromycin (500 mg once daily) with or without rifabutin (300 mg once daily).108 c


Secondary prophylaxis to prevent MAC recurrence usually continued for life in HIV-infected adults.108


Consideration can be given to discontinuing such prophylaxis after ≥12 months in those who remain asymptomatic with respect to MAC and have an increase in CD4+ T-cell count to >100/mm3 that has been sustained for ≥6 months.108 c Reinitiate prophylaxis if CD4+ T-cell count decreases to <100/mm3.108 c


Mycobacterium kansasii and Other Mycobacterial Infections†

Treatment of Pulmonary or Disseminated Infections Caused by Rifampin-susceptible M. kansasii†

Oral

15 mg/kg once daily in conjunction with rifampin (10 mg/kg [up to 600 mg] daily), isoniazid (5 mg/kg [up to 300 mg] daily), and pyridoxine (50 mg daily) recommended by ATS and IDSA.107


Continue until patient has been culture negative on treatment for 1 year.107 A longer duration may be needed in HIV-infected individuals with disseminated infections.107


Treatment of M. marinum Infections†

Oral

15–25 mg/kg daily in conjunction with rifampin (600 mg daily) and/or clarithromycin.107 i j l


Optimal duration of treatment not known; continue for 3–6 months or until at least 1–2 months after resolution of symptoms.107 i j l


Prescribing Limits


Pediatric Patients


Tuberculosis

Treatment of Active (Clinical) Tuberculosis in Children†

Oral

Maximum 1 g per dose recommended by ATS, CDC, and IDSA for once-daily or twice-weekly regimens;106 d maximum 2.5 g per dose recommended by AAP and others for once-daily or twice-weekly regimens.109 h


Mycobacterium avium Complex (MAC) Infections in Children†

Oral

Maximum 1 g once daily for treatment of disseminated MAC infections.d Maximum 900 mg once daily for prevention of MAC recurrence (secondary prophylaxis).108


Special Populations


Renal Impairment


Reduce dosage based on degree of renal impairment and serum concentrations of the drug.103 106 c e h


Some experts recommend 15 mg/kg once every 24–36 hours in adults with Clcr 10–50 mL/minute, 15 mg/kg once every 48 hours in those with Clcr <10 mL/minute, and 15 mg/kg 3 times weekly (after hemodialysis) in those undergoing hemodialysis.c Others recommend 15–20 mg/kg 3 times weekly (after dialysis) in adults with end-state renal disease (Clcr <30 mL/minute, on hemodialysis).106


In children with renal impairment, some experts recommend that the usual dose be given once every 24 hours in those with Clcr >50 mL/minute or once every 24–36 hours in those with Clcr 10–50 mL/minute.h In children with Clcr <10 mL/minute, these experts recommend that a decreased dose be given once every 48 hours.h Supplemental doses are recommended after hemodialysis.h


Cautions for Myambutol


Contraindications



  • Known hypersensitivity to ethambutol or any ingredient in the formulation.103 e




  • Optic neuritis, unless clinical judgment deems it necessary to use the drug.103 e




  • Patients unable to appreciate and report visual adverse effects or changes in vision (e.g., young children, unconscious patients).103 (See Pediatric Use under Cautions.)



Warnings/Precautions


Warnings


Ocular Effects

Decreased visual acuity, constriction of visual fields, central and peripheral scotomas, and loss of red-green color discrimination reported.103 106 a e May be due to optic neuritis, but has occurred in the absence of a diagnosis of optic or retrobulbar neuritis.103 e May be related to dose and duration of treatment.103 106 e


Perform ophthalmic evaluation (ophthalmoscopy, finger perimetry, test for color discrimination) at baseline and periodically during treatment.103 106 e Test each eye separately and together since change in visual acuity may be unilateral or bilateral.103 e Evaluate monthly in patients receiving >15 mg/kg daily, in those receiving the drug for >2 months, and in those with renal impairment.103 106 e


Use with caution in patients with ocular defects (e.g., cataracts, recurrent ocular inflammatory conditions, optic neuritis, diabetic retinopathy) that make visual changes difficult to detect or evaluate; weigh benefits versus possible visual deterioration in these patients.103 e


Discontinue if substantial changes in visual acuity occur.103 e Changes in visual acuity usually reversible (over several weeks or months), but irreversible blindness has been reported.103 e


Hepatic Effects

Liver toxicities, including fatalities, have been reported.103


Perform baseline and periodic assessment of hepatic function.103 e


Sensitivity Reactions


Anaphylactoid reactions, dermatitis, pruritus reported.103


General Precautions


Precautions Related to Treatment of Tuberculosis

Should not be used alone for the treatment of active TB; must be given in conjunction with other antituberculosis agents.106


Clinical specimens for microscopic examination and mycobacterial cultures and in vitro susceptibility testing should be obtained prior to initiation of antituberculosis therapy and periodically during treatment to monitor therapeutic response.106 The antituberculosis regimen should be modified as needed.106 Patients with positive cultures after 4 months of treatment should be considered to have failed treatment (usually as the result of noncompliance or drug-resistant TB).106


Compliance with the full course of antituberculosis therapy and all drugs included in the multiple-drug regimen is critical.106 Missed doses increase the risk of treatment failure and increase the risk that M. tuberculosis will develop resistance to the antituberculosis regimen.106


To ensure compliance, ATS, CDC, IDSA, and AAP recommend that directly observed (supervised) therapy (DOT) be used for treatment of active (clinical) TB whenever possible, especially when intermittent regimens are used, when the patient is immunocompromised or infected with HIV, or when drug-resistant M. tuberculosis is involved.106 109 c d


Laboratory Monitoring

Assess organ system function (e.g., renal, hepatic, hematopoietic) at baseline and periodically during treatment.103 e


Specific Populations


Pregnancy

Category C.103


Ophthalmic abnormalities have been reported in infants born to women who received antituberculosis regimens that included ethambutol during pregnancy.103


The ATS, CDC, IDSA, AAP and others consider ethambutol safe for use in pregnant women;106 108 109 AAP states potential benefits outweigh the risks to the infant.109


Lactation

Distributed into milk; use only if possible benefits outweigh potential risks.103


AAP considers ethambutol compatible with breast-feeding.b


Pediatric Use

Safety not established in children <13 years of age; manufacturers do not recommend use in this age group.103 e Has been used in pediatric patients without unusual adverse effects.d


ATS, CDC, IDSA, and AAP state that ethambutol can be used safety in older children, but should be used with caution in children in whom it may be difficult to monitor visual acuity (e.g., <5 years of age).106 109 If used in pediatric patients, perform ophthalmic evaluations once monthly during treatment.d


Geriatric Use

No substantial differences in safety and efficacy relative to younger adults, but increased sensitivity in this age group cannot be ruled out.103


Hepatic Impairment

ATS, CDC, and IDSA state that ethambutol can be used safely in patients with hepatic disease.106


Renal Impairment

Use with caution; dosage reduction based on serum concentrations is advised.103 e Closely monitor visual acuity and color discrimination (i.e., monthly).103 106 (See Renal Impairment under Dosage and Administration.)


Common Adverse Effects


Ophthalmic effects (decreased visual acuity, scotoma, color blindness, visual defect), joint pain, GI effects (anorexia, nausea, vomiting, GI upset, abdominal pain), fever, malaise, headache, dizziness, mental confusion.103 e


Interactions for Myambutol


Specific Drugs












Drug



Interaction



Comments



Antacids



Aluminum-containing antacids: Decreased ethambutol serum concentrations and urinary excretion; possible decreased oral absorption of the antimycobacterial103



Administer aluminum-containing antacids ≥4 hours after ethambutol103



Rifabutin



Pharmacokinetic interaction unlikelyf


Myambutol Pharmacokinetics


Absorption


Bioavailability


75–80% of an oral dose is absorbed from the GI tract;a peak plasma concentrations achieved within 2–4 hours.103 e


Food


Food does not appear to affect absorption.103 e


Special Populations


Serum concentrations are higher in patients with renal impairment.a


Distribution


Extent


Widely distributed into most body tissues and fluids.a Highest concentrations are found in erythrocytes, kidneys, lungs, and saliva; lower drug concentrations are found in ascitic fluid, pleural fluid, brain, and CSF.a


Crosses the placenta and is distributed into cord blood and amniotic fluid.100


Distributed into milk.103


Plasma Protein Binding


8–22%.a


Elimination


Metabolism


Undergoes oxidation in the liver to an aldehyde intermediate which is converted to a dicarboxylic acid derivative.103 e


Elimination Route


Excreted in urine as unchanged drug (50%) and metabolites (8–15%) and in feces as unchanged drug (20–22%).103 e


Removed by peritoneal dialysis and to a lesser extent by hemodialysis.a


Half-life


3.3 hours.a


Special Populations


Half-life prolonged in patients with impaired renal or hepatic function.a Half-life may be ≥7 hours in patients with renal failure.a


Stability


Storage


Oral


Tablets

15–30°Ce or 20–25°C103 , depending on the manufacturer. Protect from light and moisture.e


Actions and SpectrumActions



  • Bacteriostatic in action.a




  • Appears to inhibit the synthesis of one or more metabolites in susceptible bacteria resulting in impairment of cellular metabolism, arrest of multiplication, and cell death.103 e




  • A highly specific agent; active only against Mycobacterium.103 a Active against M. tuberculosis,a M. avium complex (MAC),a M. bovis,a M. kansasii,107 a g and some strains of M. fortuitum.a Although M. marinum may be susceptible,107 a resistance has been reported.k Active in vitro against M. gordonae,107 M. malmoense,107 and M. smegmatis.107 Has limited activity against M. genavense.107 M. haemophilum107 and some strains of M. xenopi are resistant.107




  • Natural and acquired resistance to ethambutol demonstrated in vitro and in vivo in strains of M. tuberculosis.103 a




  • No evidence of cross-resistance with other currently available antimycobacterials.103 e



Advice to Patients



  • Advise patients that poor compliance with antituberculosis regimens can result in treatment failure and development of drug-resistant TB, which can be life-threatening and lead to other serious health risks.106




  • Importance of completing full course of therapy; importance of not missing any doses.103




  • Importance of promptly informing clinicians of any change in visual acuity.103 e




  • Importance of informing clinicians of existing or contemplated therapy, including prescription and OTC drugs, as well as any concomitant illnesses.103




  • Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.103




  • Importance of informing patients of other important precautionary information.103 (See Cautions.)



Preparations


Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.




























Ethambutol Hydrochloride

Routes



Dosage Forms



Strengths



Brand Names



Manufacturer



Oral



Tablets, film-coated



100 mg



Ethambutol Tablets



VersaPharm



Myambutol



X-Gen



400 mg



Ethambutol Tablets



Barr, VersaPharm



Myambutol (scored)



X-Gen


Comparative Pricing


This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.


Ethambutol HCl 400MG Tablets (VERSAPHARM): 30/$55.99 or 90/$153.98



Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.


The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions February 2008. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.


† Use is not currently included in the labeling approved by the US Food and Drug Administration.




References



100. Holdiness MR. Transplacental pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet. 1987; 13:125-9. [IDIS 233465] [PubMed 3304771]



102. Brock PG, Roach M. Antituberculosis drugs during pregnancy. Lancet. 1981; 1:102.



103. X-Gen. Myambutol (ethambutol hydrochloride) tablets USP prescribing information. Northport, NY; 2004 Jun.



104. Gulliford M, Mackay AD, Prowse K. Cholestatic jaundice caused by ethambutol. BMJ. 1986; 292:866. [IDIS 213885] [PubMed 3083914]



105. US Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recomm Rep. 1993; 42(RR-7):1-8.



106. Centers for Disease Control and Prevention. Treatment of tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR Recomm Rep. 2003; 52(No. RR-11):1-77.



107. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007; 175:367-416. [PubMed 17277290]



108. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA) Prevention of Opportunistic Infections Working Group. 2001 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons with human immunodeficiency virus. From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website ()



109. American Academy of Pediatrics. 2006 Red Book: Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006.



a. AHFS drug information 2007. McEvoy GK. Ethambutol. Bethesda, MD. American Society of Health-System Pharmacists;2007:550-2.



b. Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation. 6th ed. Philadelphia; PA: Lippincott Wiliams & Wilkins; 2002:509-10.



c. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Recomm Rep. 2004; 53(RR-15):1-112.



d. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-exposed and infected children: recommendations from CDC, the National Institutes of Health, and the Infectious Diseases Society of America. MMWR Recomm Rep. 2004; 53(RR-14):1-92.



e. VersaPharm. Ethambutol hydrochloride tablets USP prescribing information. Marietta, GA; 2001 Feb.



f. Pfizer. Mycobutin (rifabutin) capsules USP prescribing information. New York, NY; 2006 Feb.



g. Shitrit D, Baum GL, Priess R et al. Pulmonary Mycobacterium kansasii infection in Israel, 1999-2004: clinical features, drug susceptibility, and outcome. Chest. 2006; 129:771-6. [PubMed 16537880]



h. Robertson J, Shilkofski N, eds. The Harriet Lane handbook: a manual for pediatric house officers. 17th ed. Philadelphia, PA: Elsevier Mosby: 2005:808-9,1058.



i. Lewis FM, Marsh BJ, von Reyn CF. Fish tank exposure and cutaneous infections due to Mycobacterium marinum: tuberculin skin testing, treatment, and prevention. Clin Infect Dis. 2003; 37:390-7. [PubMed 12884164]



j. Rallis E, Koumantaki-Mathioudaki E. Treatment of Mycobacterium marinum cutaneous infections. Exp Opin Pharmacother. 2007; 8:2965-78.



k. Aubry A, Jarlier V, Escolano S et al. Antibiotic susceptibility pattern of Mycobacterium marinum. Antimicrob Agents Chemother. 2000; 44:3133-6. [PubMed 11036036]



l. Edelstein H. Mycobacterium marinum skin infections. Report of 31 cases and review of the literature. Arch Intern Med. 1994; 154:1359-64. [PubMed 8002687]



More Myambutol resources


  • Myambutol Side Effects (in more detail)
  • Myambutol Use in Pregnancy & Breastfeeding
  • Drug Images
  • Myambutol Drug Interactions
  • Myambutol Support Group
  • 0 Reviews for Myambutol - Add your own review/rating


  • Myambutol Concise Consumer Information (Cerner Multum)

  • Myambutol Advanced Consumer (Micromedex) - Includes Dosage Information

  • Myambutol MedFacts Consumer Leaflet (Wolters Kluwer)

  • Ethambutol Prescribing Information (FDA)



Compare Myambutol with other medications


  • Mycobacterium avium-intracellulare, Prophylaxis
  • Mycobacterium avium-intracellulare, Treatment
  • Tuberculosis, Active